Trial Profile
A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms DAVE
- 01 Mar 2023 Results of post hoc analysis assessing relationship between baseline retinal non-perfusion area (NPA) and retinal vascular bed area (RVBA) on ultra-wide field fluorescein angiography (UWF FA) and long-term response to intravitreal ranibizumab therapy in diabetic macular oedema published in the Eye
- 31 Aug 2018 Status changed from active, no longer recruiting to completed.
- 01 Aug 2017 Results assessing distribution of nonperfusion area from 29 treatment-naive patients of this trial published in the American Journal of Ophthalmology